Small Molecules

Rivaroxaban

Quality Solutions

Category: Anticoagulants



Authorized Distributor

MONOGRAPH 1

RIVAROXABAN Official as of 01-Dec-2022	
USP Rivaroxaban R-Enantiomer RS	USP-1604541
USP Rivaroxaban RS	USP-1604530
USP Rivaroxaban Related Compound B RS	USP-1604552
USP Rivaroxaban Related Compound D RS	USP-1604563
USP Rivaroxaban Related Compound G RS	USP-1604596
USP Rivaroxaban Related Compound J RS	USP-1604574

MONOGRAPH 2

RIVAROXABAN TABLETS | *NEW* Official as of 01-May-2023	
USP Rivaroxaban RS	USP-1604530
USP Rivaroxaban Related Compound H RS	USP-1604585

** Documents in PF Online are not official and not suitable to demonstrate compliance. They may never become official.*

PHARMACEUTICAL ANALYTICAL IMPURITY(IES)*	
USP Rivaroxaban Glycolic Acid Analog PAI	USP-1A01170
USP Rivaroxaban Open Oxomorpholine Ring PAI	USP-1A02240
USP Rivaroxaban Open Ring Methylamine PAI	USP-1A00650
USP Rivaroxaban Phthalamide PAI	USP-1A00660
USP Rivaroxaban Open Ring PAI	USP-1A00670
USP Rivaroxaban Amine PAI	USP-1A01160
USP Chlorothiophene Carboxylic Acid PAI	USP-1A01180
USP Rivaroxaban N-Acyl Glycolic Acid PAI	USP-1A01190
USP Chloro N-methylthiophene Carboxamide PAI	USP-1A01450
USP Rivaroxaban Open Chain Dithiophene Analog PAI	USP-1A01460
USP Rivaroxaban Desmorpholinone Analog PAI	USP-1A01470

[#] Pharmaceutical Analytical Impurities (PAI products) are released using a process developed by USP's subject matter experts. The release process is based on internal policies, standard operating procedures, and requirements as defined by USP's Quality Management System. USP is an ISO 9001:2015 certified facility. PAI products are different from official USP Reference Standards. PAI products are not required for compendial compliance.

01-Oct-2023. For publications related to **Rivaroxaban** in *PF* online after this date, please visit the integrated *USP-NF/PF* online.

Small Molecules

Rivaroxaban

Quality Solutions

Category: Anticoagulants



Authorized Distributor

PHARMACEUTICAL ANALYTICAL IMPURITY(IES)*	
USP Desthiophenerivaroxaban Methylcarbamate Analog PAI	USP-1A01480
USP Methylisoindolinedione PAI	USP-1A01490
USP Desthiophenerivaroxaban Phthalimodo Analog PAI	USP-1A01500
USP Rivaroxaban Desthiophene Analog PAI	USP-1A01510
USP Rivaroxaban N-methylphthalamido Analog PAI	USP-1A01520
USP Aminophenylmorpholinone PAI	USP-1A01530
USP (S)-Glycidyl Phthalimide PAI	USP-1A01540
USP Rivaroxaban Open Ring S-isomer PAI	USP-1A01550
USP Chlorothiophene Aldehyde PAI	USP-1A01560
USP Rivaroxaban Phthalimido Analog PAI	USP-1A01570
USP Dichlorothiophene Carboxylic Acid PAI	USP-1A01580
USP Nitrophenylcholrothiophene Carboxylate PAI	USP-1A01590
USP Dihthalimido Morpholinone Analog PAI	USP-1A01600
USP Aminophenylmorpholin-2-one PAI	USP-1A01610
USP Rivaroxaban Ethyl Carbamate PAI	USP-1A02250
USP Dichlorothienoic Acid PAI	USP-1A02260
USP Rivaroxaban Phthalimide PAI	USP-1A02270
USP Rivaroxaban Isomer PAI	USP-1A02280
USP Rivaroxaban Phthalimido Ethyl Ester Analog PAI	USP-1A02290
USP Rivaroxaban Ethylamino Analog PAI	USP-1A02300

[#] *Pharmaceutical Analytical Impurities (PAI products) are released using a process developed by USP's subject matter experts. The release process is based on internal policies, standard operating procedures, and requirements as defined by USP's Quality Management System. USP is an ISO 9001:2015 certified facility. PAI products are different from official USP Reference Standards. PAI products are not required for compendial compliance.*

01-Oct-2023. For publications related to **Rivaroxaban** in *PF* online after this date, please visit the integrated *USP-NF/PF* online.